EGFR and glioblastoma: However, the combination of AZD-9291 and GDC-0084 simultaneously inhibited the activation of the EGFR/ERK and AKT/mTOR signaling pathways, and more effectively inhibited GBM growth, compared to monotherapy (Fig. 5D).